HS-25 clinical trials
Also written HS-25.
How each study uses HS-25 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HS-25
- 2
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Zhejiang Hisun Pharmaceutical Co. Ltd. (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses HS-25 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety Study of HS-25 in Chinese Adults With Primary HypercholesterolemiaCompletedPhase 3Zhejiang Hisun Pharmaceutical Co. Ltd.NCT03413462Written as HS-25
- Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart DiseasesCompletedPhase 3Zhejiang Hisun Pharmaceutical Co. Ltd.NCT03433196Written as HS-25 and Atorvastatin
- Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary HypercholesterolemiaStatus unknownPhase 3Zhejiang Hisun Pharmaceutical Co. Ltd.NCT03464682Written as HS-25 10mg
- A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary HypercholesterolemiaCompletedPhase 2Zhejiang Hisun Pharmaceutical Co. Ltd.NCT02087917Written as HS-25